LeMaitre Vascular (LMAT) Stock Price, News & Analysis

Company Overview

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Key Stats

• Today's Range: $90.61 to $93.60
• 50-Day Range: $85.64 to $107.97
• 52-Week Range: $52.88 to $109.58
• Volume: 455,200 shs
• Average Volume: 131,709 shs
• Market Capitalization: $2.07 billion
• P/E Ratio: 50.34
• Dividend Yield: 0.69%
• Price Target: $94.57
• Consensus Rating: Moderate Buy

LeMaitre Vascular Stock Analysis - MarketRank™

LeMaitre Vascular scored higher than 60% of companies evaluated by MarketBeat, and ranked 393rd out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

LeMaitre Vascular has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

LeMaitre Vascular has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 11.34%

Earnings Growth

Earnings for LeMaitre Vascular are expected to grow by 11.34% in the coming year, from $1.94 to $2.16 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of LeMaitre Vascular is 50.34, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.80.

Price to Earnings Ratio vs. Sector

The P/E ratio of LeMaitre Vascular is 50.34, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 99.05.

Price to Earnings Growth Ratio

LeMaitre Vascular has a PEG Ratio of 2.47. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

LeMaitre Vascular has a P/B Ratio of 6.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.11% of the float of LeMaitre Vascular has been sold short.

Short Interest Ratio / Days to Cover

LeMaitre Vascular has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in LeMaitre Vascular has recently increased by 11.34%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

LeMaitre Vascular has a dividend yield of 0.69%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

LeMaitre Vascular has been increasing its dividend for 13 years.

Dividend Coverage

The dividend payout ratio of LeMaitre Vascular is 34.97%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, LeMaitre Vascular will have a dividend payout ratio of 29.63% next year. This indicates that LeMaitre Vascular will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.11% of the float of LeMaitre Vascular has been sold short.

Short Interest Ratio / Days to Cover

LeMaitre Vascular has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in LeMaitre Vascular has recently increased by 11.34%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.71

News Sentiment

LeMaitre Vascular has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for LeMaitre Vascular this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for LMAT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added LeMaitre Vascular to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, LeMaitre Vascular insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $380,512.00 in company stock.

Percentage Held by Insiders

10.79% of the stock of LeMaitre Vascular is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

84.64% of the stock of LeMaitre Vascular is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LMAT Stock Analysis - Frequently Asked Questions

How have LMAT shares performed this year?

LeMaitre Vascular's stock was trading at $56.76 at the start of the year. Since then, LMAT stock has increased by 62.3% and is now trading at $92.12.
View the best growth stocks for 2024 here.

How were LeMaitre Vascular's earnings last quarter?

LeMaitre Vascular, Inc. (NASDAQ:LMAT) released its earnings results on Thursday, October, 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. The company's revenue was up 15.6% compared to the same quarter last year.

Does LeMaitre Vascular have any subsidiaries?

The following companies are subsidiaries of LeMaitre Vascular: Artegraft, CardioCel, Tru-Incise (Eze-Sit) US, VascuCel, LeMaitre Cardial SAS, Syntel and Python, ProCol, and more.

Who are LeMaitre Vascular's major shareholders?

LeMaitre Vascular's top institutional shareholders include Conestoga Capital Advisors LLC (8.81%), Copeland Capital Management LLC (5.18%), Geneva Capital Management LLC (3.91%) and State Street Corp (3.66%). Insiders that own company stock include George W Lemaitre, David B Roberts, Joseph P Pellegrino Jr, Trent G Kamke, Bridget A Ross and John A Roush.
View institutional ownership trends.

How do I buy shares of LeMaitre Vascular?

Shares of LMAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of LeMaitre Vascular own?

Based on aggregate information from My MarketBeat watchlists, some other companies that LeMaitre Vascular investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

• Last Earnings: 10/31/2024
• Ex-Dividend for 12/5 Dividend: 11/21/2024
• Dividend Payable: 12/05/2024
• Today: 12/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: N/A
• Current Symbol: NASDAQ:LMAT
• CUSIP: N/A
• CIK: 1158895
• Web: www.lemaitre.com
• Phone: (781) 221-2266
• Fax: 781-425-5049
• Employees: 614
• Year Founded: 1983

Price Target and Rating

• Average Stock Price Target: $94.57
• High Stock Price Target: $105.00
• Low Stock Price Target: $75.00
• Potential Upside/Downside: +2.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $1.83
• Trailing P/E Ratio: 50.34
• Forward P/E Ratio: 47.48
• P/E Growth: 2.47
• Net Income: $30.10 million
• Net Margins: 19.40%
• Pretax Margin: 25.43%
• Return on Equity: 13.15%
• Return on Assets: 11.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.74
• Quick Ratio: 5.52

Sales & Book Value

• Annual Sales: $213.03 million
• Price / Sales: 9.72
• Cash Flow: $1.63 per share
• Price / Cash Flow: 56.56
• Book Value: $13.38 per share
• Price / Book: 6.88

Miscellaneous

• Outstanding Shares: 22,484,000
• Free Float: 20,058,000
• Market Cap: $2.07 billion
• Optionable: Optionable
• Beta: 0.93